id: mortensen2014_coenzyme
title: The Effect of Coenzyme Q 10 on Morbidity and Mortality in Chronic Heart
  Failure
authors:
- Mortensen Svend A.
- Rosenfeldt Franklin
- Kumar Adarsh
- Dolliner Peter
- Filipiak Krzysztof J.
- Pella Daniel
- Alehagen Urban
- Steurer GÃ¼nter
- Littarru Gian P.
year: 2014
reference_type: Journal article
keywords:
- chronic
- coenzyme
- failure
- heart
- morbidity
- mortality
hard_claims:
- summary: "CoQ10 supplementation reduced major adverse cardiovascular events by 50% compared to placebo in chronic heart failure patients"
  choice: coq10
  evidence_type: Randomized controlled trial
  effect_size: 0.50
  effect_ci_lower: 0.32
  effect_ci_upper: 0.80
  outcome: "major adverse cardiovascular events"
  population: "patients with moderate to severe chronic heart failure"
  sample_size: 420
  followup_years: 2.0
  notes: "Q-SYMBIO trial; randomized double-blind; CoQ10 300mg/day; p=0.003"
- summary: "CoQ10 supplementation reduced cardiovascular mortality by 43% in chronic heart failure patients"
  choice: coq10
  evidence_type: Randomized controlled trial
  effect_size: 0.57
  effect_ci_lower: null
  effect_ci_upper: null
  outcome: "cardiovascular mortality"
  population: "patients with moderate to severe chronic heart failure"
  sample_size: 420
  followup_years: 2.0
  notes: "9% vs 16% mortality; p=0.026"
- summary: "CoQ10 supplementation reduced all-cause mortality by 44% in chronic heart failure patients"
  choice: coq10
  evidence_type: Randomized controlled trial
  effect_size: 0.56
  effect_ci_lower: null
  effect_ci_upper: null
  outcome: "all-cause mortality"
  population: "patients with moderate to severe chronic heart failure"
  sample_size: 420
  followup_years: 2.0
  notes: "10% vs 18% mortality; p=0.018"
soft_claims: []
journal: 'JACC: Heart Failure'
volume: '2'
issue: '6'
pages: 641-649
doi: 10.1016/j.jchf.2014.06.008
pmid: ''
url: https://www.jacc.org/doi/10.1016/j.jchf.2014.06.008
summary: "Q-SYMBIO trial: randomized double-blind RCT of CoQ10 (300mg/day) in 420 patients with moderate to severe chronic heart failure over 2 years. Found 50% reduction in major adverse cardiovascular events (HR 0.50), 43% reduction in cardiovascular mortality, and 44% reduction in all-cause mortality. Significant improvement in NYHA functional class."
